TY - JOUR
T1 - Europium-154 contamination levels in Samarium-153-EDTMP for radionuclide therapy
AU - Moro, L.
AU - Fantinato, D.
AU - Frigerio, F.
AU - Shamhan, G.
AU - Angelovski, G.
PY - 2006/5/1
Y1 - 2006/5/1
N2 -
153Sm-EDTMP, a useful non toxic bone seeking isotope in the palliative radionuclide therapy for bone metastases, is produced by neutron activation of enriched of
152Sm
2O
3 targets. During the large-scale formation of
153Sm, however, there is a co-production of some long-lived radio nuclides, among which
154Eu is a major and inevitable radionuclide impurity. The level of
154Eu contamination was evaluated performing a gamma-ray spectrometry of a radiopharmaceutical sample and the urine of an administered patient. As expected, gamma-ray spectra revealed the presence of
153Eu in all the samples. The specific activity of
153Eu in the urine sample collected at 6 hours after injection is 21 Bq/ml and is less than 1 Bq/ml in 24 hr. The contamination levels of
153Eu, normalized to the corresponding activity of
153Sm, were 0.0012% in the residual and in the first urine sample and 0.0017% and 0.0031% at 30 and 54 hours after administration, respectively. The results of this study show that the level of the long-lived
153Eu impurity is not a limitation in the metastatic bone pain palliation due to the additional radiation dose burden, but could pose a cause of concern in case of discharging.
AB -
153Sm-EDTMP, a useful non toxic bone seeking isotope in the palliative radionuclide therapy for bone metastases, is produced by neutron activation of enriched of
152Sm
2O
3 targets. During the large-scale formation of
153Sm, however, there is a co-production of some long-lived radio nuclides, among which
154Eu is a major and inevitable radionuclide impurity. The level of
154Eu contamination was evaluated performing a gamma-ray spectrometry of a radiopharmaceutical sample and the urine of an administered patient. As expected, gamma-ray spectra revealed the presence of
153Eu in all the samples. The specific activity of
153Eu in the urine sample collected at 6 hours after injection is 21 Bq/ml and is less than 1 Bq/ml in 24 hr. The contamination levels of
153Eu, normalized to the corresponding activity of
153Sm, were 0.0012% in the residual and in the first urine sample and 0.0017% and 0.0031% at 30 and 54 hours after administration, respectively. The results of this study show that the level of the long-lived
153Eu impurity is not a limitation in the metastatic bone pain palliation due to the additional radiation dose burden, but could pose a cause of concern in case of discharging.
UR - http://www.scopus.com/inward/record.url?scp=33745302606&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33745302606&partnerID=8YFLogxK
U2 - 10.1088/1742-6596/41/1/063
DO - 10.1088/1742-6596/41/1/063
M3 - Article
AN - SCOPUS:33745302606
SN - 1742-6588
VL - 41
SP - 535
EP - 537
JO - Journal of Physics: Conference Series
JF - Journal of Physics: Conference Series
IS - 1
M1 - 063
ER -